Teva sells off women’s health assets for $1.38bn
Teva has sold the remaining assets in its speciality global women’s health portfolio for $1.38 billion.
Read More
Tag: CVC
Allergan, Novartis sign NASH clinical trials pact
Allergan is expanding its research and development programme on non-alcoholic steatohepatitis (NASH) through a collaboration with Novartis that will test a new combination therapy approach for the condition.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
